Prevail Therapeutics Announces Pricing of Initial Public Offering
NEW YORK–(BUSINESS WIRE)–Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public […]